Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (20 quarters reported)
$158M in Q4 2020 → $81.3M now. Hover for any quarter.
As reported for the quarter ended September 30, 2025. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Beam Therapeutics Inc | 67.7% | Unchanged | 2,266,934 | $55M |
| Lyell Immunopharma Inc | 20.1% | New | 1,008,116 | $16.4M |
| Prime Medicine Inc | 12.2% | Unchanged | 1,792,210 | $9.93M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2025 · filed November 12, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Lyell Immunopharma Inc | New | +1,008,116 | +$16.4M | 20.1% |
| Lyell Immunopharma Inc | Exited | −1,008,116 | −$8.91M | — |
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Lyell Immunopharma Inc | Trimmed | −19,154,216 | −$169M | 17.2% |
quarter ended March 31, 2025 · filed May 13, 2025
No position changes this quarter.
quarter ended December 31, 2024 · filed February 14, 2025
No position changes this quarter.
quarter ended September 30, 2024 · filed November 08, 2024
No position changes this quarter.
quarter ended June 30, 2024 · filed August 13, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Beam Therapeutics Inc | Trimmed | −80,000 | −$1.87M | 58.0% |
quarter ended March 31, 2024 · filed May 14, 2024
No position changes this quarter.
quarter ended December 31, 2023 · filed February 14, 2024
No position changes this quarter.
Loading...
